Caicun Zhou

机构：Tongji University, Shanghai Stomatological Hospital, First Affiliated Hospital of Guangzhou Medical University, Shanghai Pulmonary Hospital, Shanghai East Hospital, State Key Laboratory of Respiratory Disease, Guangzhou Medical University · ORCID：0000-0002-6958-0766

发表论文 378 篇 · 总被引 12074 次 · h-index 51

代表论文

• The changing treatment landscape of EGFR-mutant non-small-cell lung cancer (2024 · Nature Reviews Clinical Oncology · 被引 159)
• Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China (2025 · The Lancet · 被引 153)
• Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial (2025 · Nature Medicine · 被引 34)
• Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer (2024 · ESMO Open · 被引 23)
• First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors (2024 · Signal Transduction and Targeted Therapy · 被引 10)
• Evaluating efficacy and safety of a novel registration-free CT-guided needle biopsy navigation system (RC 120): A multicenter, prospective clinical trial (2024 · Lung Cancer · 被引 7)